Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pinus nigra pollen
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral, Dermal, Intradermal, Subcutaneous, Sublingual, Topical
01
Overview
Pinus nigra pollen is an allergenic extract derived from the pollen of the *Pinus nigra* (black pine) plant. It is primarily utilized as a diagnostic biologic for identifying allergic sensitivities in patients suspected of having pine pollen allergies. The extract is used in clinical settings for in-vivo diagnostic procedures, such as skin prick testing or intradermal testing, where it elicits a localized type I hypersensitivity reaction (wheal-and-flare) in sensitized individuals. It may also be used in-vitro to determine the presence of allergen-specific IgE. The product was first approved in the United States in 1967 and is regulated under biologics license applications (BLA101376 and BLA102223).
- Other names
- black pine pollenPinus nigra pollen extract
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on pinus nigra pollen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pinus nigra pollen.